Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
December 22, 2014
Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration
December 22, 2014
Bristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)
December 17, 2014
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27
December 10, 2014
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors
December 6, 2014
Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma
November 26, 2014
Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C
November 24, 2014
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types
November 17, 2014
Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results from the First Part of the Phase 3 ANNEXA™-A Studies of Investigational Andexanet Alfa with Eliquis (apixaban)
November 17, 2014
Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA)
November 16, 2014
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial
November 16, 2014
Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naive Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial
November 8, 2014
ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
November 7, 2014
Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting
November 4, 2014
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference
November 3, 2014
Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis
October 30, 2014
Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
October 30, 2014
Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology
October 28, 2014
Bristol-Myers Squibb Enters into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. and its Novel HER2-Targeted Therapy
October 24, 2014
Bristol-Myers Squibb Reports Third Quarter 2014 Financial Results
October 13, 2014
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss CMSTO Highlights
October 13, 2014
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma
October 13, 2014
Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO(R) (nivolumab) and IMBRUVICA(R)(ibrutinib) in Non-Hodgkin Lymphoma
October 8, 2014
Bristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S.
October 6, 2014
Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer (NSCLC)
October 6, 2014
Bristol-Myers Squibb and MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia and Hematologic Malignancies
October 3, 2014
Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology
October 3, 2014
Bristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014(TM) Showcasing Continued Innovation in Virology
October 1, 2014
Bristol-Myers Squibb to Announce Results for Third Quarter on October 24
September 30, 2014
Bristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential
September 29, 2014
European Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer
September 29, 2014
Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presented at the ESMO 2014 Congress; First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 26, 2014
Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union
September 22, 2014
Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers
September 16, 2014
Bristol-Myers Squibb Announces Dividend
September 11, 2014
Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
September 2, 2014
Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
August 30, 2014
Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)
August 27, 2014
European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection
August 21, 2014
U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy
August 20, 2014
Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen
August 4, 2014
Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U.S. Academic Research Institutions
July 29, 2014
European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
July 24, 2014
Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results
July 23, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Co., Ltd. Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
July 17, 2014
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis® (apixaban) in Patients with NVAF Undergoing Cardioversion
July 17, 2014
Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis(R) (apixaban) in Patients with NVAF Undergoing Cardioversion
July 10, 2014
Bristol-Myers Squibb Announces Plans for Third Quarter Submission of a Biologics License Application for Opdivo® (nivolumab), an Investigational PD-1 Immune Checkpoint Inhibitor, for Previously Treated Advanced Melanoma
July 7, 2014
Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza® (daclatasvir) and Sunvepra® (asunaprevir) Dual Regimen
July 7, 2014
Japan Approves First All-Oral, Interferon- and Ribavirin-Free Hepatitis C Treatment, Daklinza(R) (daclatasvir) and Sunvepra(R) (asunaprevir) Dual Regimen
July 1, 2014
Bristol-Myers Squibb to Announce Results for Second Quarter on July 24
June 27, 2014
Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
June 27, 2014
Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union
June 27, 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
June 27, 2014
Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza(R) (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union
June 24, 2014
Phase 3 First-Line Melanoma Study of Nivolumab, an Investigational PD-1 Checkpoint Inhibitor, Demonstrates Superior Overall Survival Compared to Dacarbazine; Study Stopped Early
June 24, 2014
Bristol-Myers Squibb Expands Access to Clinical Trial Data Through Collaboration with Academic Research Institute
June 17, 2014
Bristol-Myers Squibb Announces Dividend
June 12, 2014
U.S. Court of Appeals Denies Appeal in Baraclude Patent Case
June 10, 2014
AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia(R) (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)
June 10, 2014
AVERT Trial Demonstrates High Rates of DAS-defined Remission with Orencia® (abatacept) in Combination with Methotrexate (MTX) in Adult Patients with Early Rheumatoid Arthritis (RA)
June 9, 2014
Giovanni Caforio, M.D., Appointed Chief Operating Officer and Elected to Board of Directors
June 3, 2014
Bristol-Myers Squibb to Take Part in Goldman Sachs 35th Annual Global Health Care Conference
June 3, 2014
Bristol-Myers Squibb and Syngene International Extend Research Collaboration
June 2, 2014
Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival
June 2, 2014
One- & Two-Year Survival Rates of 94% and 88% Announced from Phase 1b Trial of Investigational PD-1 Checkpoint Inhibitor Nivolumab and Yervoy® (ipilimumab) in Advanced Melanoma; Ongoing Phase 2/3 Trials to Confirm Results
June 2, 2014
One- & Two-Year Survival Rates of 94% and 88% Announced from Phase 1b Trial of Investigational PD-1 Checkpoint Inhibitor Nivolumab and Yervoy(R) (ipilimumab) in Advanced Melanoma; Ongoing Phase 2/3 Trials to Confirm Results
June 2, 2014
Phase 3 Study Evaluating Yervoy(R) (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival
May 27, 2014
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody™ Therapeutics Against Multiple Immuno-Oncology Targets
May 27, 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
May 27, 2014
Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody(TM) Therapeutics Against Multiple Immuno-Oncology Targets
May 21, 2014
Bristol-Myers Squibb to Present New Remission Data on ORENCIA® (abatacept) and Clazakizumab at The European League Against Rheumatism (EULAR) 2014 Annual Meeting
May 21, 2014
Bristol-Myers Squibb to Present New Remission Data on ORENCIA(R) (abatacept) and Clazakizumab at The European League Against Rheumatism (EULAR) 2014 Annual Meeting
May 19, 2014
Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma
May 16, 2014
Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 14, 2014
In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy(R) (ipilimumab)
May 14, 2014
In Phase 2 and 1b Renal Cell Carcinoma Trials, Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity as a Single Agent and in Combination Regimen with Yervoy® (ipilimumab)
May 14, 2014
Bristol-Myers Squibb Announces Two- and Three-Year Survival Data for Nivolumab, an Investigational PD-1 Immune Checkpoint Inhibitor, from Advanced Melanoma Cohort of a Phase 1b Study
May 14, 2014
Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Showed Antitumor Activity in Previously Treated and Chemotherapy-Naïve Patients in Phase 1b Non-Small Cell Lung Cancer Trials
May 14, 2014
Investigational PD-1 Immune Checkpoint Inhibitor Nivolumab Receives U.S. FDA Breakthrough Therapy Designation for Hodgkin Lymphoma
May 14, 2014
Bristol-Myers Squibb and Celldex Therapeutics Announce Clinical Trial Collaboration to Evaluate the Combination of Investigational Immunotherapies Nivolumab and Varlilumab
May 12, 2014
Bristol-Myers Squibb to Present at UBS Global Healthcare Conference
May 6, 2014
Bristol-Myers Squibb Announces Retirement of Brian Daniels
May 5, 2014
Bristol-Myers Squibb Continues to Lead the Advancement of Immuno-Oncology with Broad Set of New Data at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting
April 29, 2014
Bristol-Myers Squibb Reports First Quarter 2014 Financial Results
April 29, 2014
Bristol-Myers Squibb Acquires iPierian, Inc.
April 24, 2014
Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List
April 22, 2014
Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement
April 14, 2014
Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1
April 10, 2014
Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients
April 7, 2014
Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C
April 1, 2014
Bristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29
March 24, 2014
Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Genotypes at The International Liver CongressTM
March 17, 2014
Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways
March 5, 2014
Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel, Investigational Attachment Inhibitor for HIV-1 Infected Treatment-Experienced Patients
March 3, 2014
Bristol-Myers Squibb Announces Dividend
March 3, 2014
Bristol-Myers Squibb Announces Charitable Donation of $1 Million to Support Immuno-Oncology Education for Patients and Caregivers
February 24, 2014
Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for All-Oral Daclatasvir Dual Investigational Regimen for Chronic Hepatitis C
February 21, 2014
In a Subanalysis, Eliquis® (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
February 20, 2014
Bristol-Myers Squibb to Present at Cowen and Company 34th Annual Global Health Care Conference
February 14, 2014
Bristol-Myers Squibb to Present at Citi 2014 Global Health Care Conference
February 5, 2014
Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference
February 3, 2014
Bristol-Myers Squibb Completes Previously Announced Sale of Global Diabetes Business to AstraZeneca
January 24, 2014
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results
January 16, 2014
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative
January 13, 2014
U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes
January 8, 2014
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga™ (dapagliflozin)
January 8, 2014
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency
January 6, 2014
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24
January 6, 2014
Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
January 3, 2014
Bristol-Myers Squibb to Take Part in Goldman Sachs Healthcare CEOs Unscripted Conference